stonks4u
Sign up free
ARDX logo

ARDX Ardelyx, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$4.06
+0.15 (+3.84%)

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phas…

Market Cap: $1.00Bwww.ardelyx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
8092103115
Aug 12Aug 13

Quote

Day Range
$3.87 – $4.07
52-Week Range
$3.86 – $8.40
Volume
$3.96M
Market Cap
$1.00B
50-Day Avg
$5.21
200-Day Avg
$5.99
Prev Close
$3.91
Open
$3.92

Valuation & Ratios

P/E Ratio
-22.42
EPS
$-0.26
P/B Ratio
8.42
P/S Ratio
3.45
Debt/Equity
1.27
Current Ratio
4.31
Dividend Yield
+0.0%
Gross Margin
+89.5%

Returns & Efficiency

Return on Equity
-36.9%
Return on Assets
-12.3%
FCF Yield
-3.1%
EV/EBITDA
-53.09

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$407.32M$-61.60M$-0.26
2024$333.62M$-39.14M$-0.17
2023$124.46M$-66.07M$-0.30
2022$52.16M$-67.21M$-0.42
2021$10.10M$-158.16M$-1.52

Social Signal Score

48
5d
48
2 mentions
—
30d
48
2 mentions
—
60d
48
2 mentions
—
90d
48
2 mentions
—
news: 2

Earnings

Thu, Oct 29(in 2 months)

Consensus estimate $-0.02 per share

4of 7 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.07 vs $-0.07miss
  • Thu, Apr 30$-0.15 vs $-0.13miss
  • Thu, Feb 19$0.02 vs $0.02beat
  • Thu, Oct 30$-0.00 vs $-0.06beat
  • Mon, Aug 4$-0.08 vs $-0.13beat
  • Thu, May 1$-0.17 vs $-0.10miss

Estimates and results for ARDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ARDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsprnewswire.com·1d ago·Negative

    Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2026 product revenue of $118.1 million and…

    View source ↗
  • Newsseekingalpha.com·3d ago·Positive

    Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force

    View source ↗